AA
| |
Affinity Asset Advisors, LLC13F | |
| Affinity Asset Advisors, LLC | |
| Last update 2025-05-15 | 95 Stocks (20 new) |
| Value $1.01 Bil | Turnover 17 % |
Affinity Asset Advisors, LLC Top Holdings of 2025-03-31
View Full List
| Ticker | | Company | Shares | Value ($1000) | Shares Change % | Weighting % | Trade Impact % | % of Shares outstanding | 3M Change % | YTD Change % | Market Cap $Mil | Industry |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
SPY
PUT
| SPDR S&P 500 ETF Trust | 400,000 | 223,756.0 | 0% | 22.050 | 0% | 0.040 | +16.86% | +7.34% | 643,153.0 | ||
IWM
PUT
| iShares Russell 2000 ETF | 300,000 | 59,847.0 | 0% | 5.900 | 0% | 0.100 | +17.95% | +1.47% | 66,253.5 | ||
XENE | Xenon Pharmaceuticals Inc | 1,328,175 | 44,560.3 | +14.38% | 4.390 | +0.55% | 1.730 | +8.30% | -15.15% | 2,552.2 | Biotechnology | |
APGE | Apogee Therapeutics Inc | 1,151,199 | 43,008.8 | +23.56% | 4.240 | +0.81% | 1.970 | +35.64% | +4.77% | 2,767.5 | Biotechnology | |
XBI
PUT
| SPDR Biotech ETF | 500,000 | 40,550.0 | 0% | 4.000 | 0% | 0.790 | +9.10% | -5.34% | 5,039.7 | ||
VRNA | Verona Pharma PLC | 615,000 | 39,046.3 | -6.82% | 3.850 | -0.30% | 0.720 | +57.57% | +97.09% | 7,792.1 | Biotechnology | |
ACLX | Arcellx Inc | 530,000 | 34,768.0 | +24.71% | 3.430 | +0.68% | 0.960 | +7.56% | -12.43% | 3,701.0 | Biotechnology | |
ALKS | Alkermes PLC | 1,000,000 | 33,020.0 | -9.09% | 3.250 | -0.41% | 0.610 | -8.88% | +0.31% | 4,757.4 | Drug Manufacturers | |
NUVL | Nuvalent Inc | 460,000 | 32,623.2 | +61.40% | 3.210 | +1.22% | 0.640 | +17.80% | +2.81% | 5,779.2 | Biotechnology | |
MDGL | Madrigal Pharmaceuticals Inc | 80,000 | 26,498.4 | -3.03% | 2.610 | -0.11% | 0.360 | -8.63% | -3.14% | 6,635.9 | Biotechnology |
Affinity Asset Advisors, LLC's Historical Top Holdings Breakdowns
Affinity Asset Advisors, LLC's Top Stock Picks
View Full List
| Ticker | | Company | Date | Action | Impact % | Price Range | Price | Price Change from Avrg% | Comment | Current Shares | Share Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
CRNX | Crinetics Pharmaceuticals Inc | 2025-03-31 | Reduce Reduce | -2.25% | 32.3 ($37.35) 53.15 | $29.80 | -20.21% | Reduce -66.9% | 152,252 | -307,748 | |
ARVN | Arvinas Inc | 2025-03-31 | Sold Out Sold Out | -1.73% | 7.02 ($15.67) 20.5 | $7.95 | -49.27% | Sold Out | 0 | -630,000 | |
SPY | SPDR S&P 500 ETF Trust | 2025-03-31 | New Buy New Buy | +1.65% | 551.42 ($587.78) 612.93 | $625.34 | 6.39% | New holding | 30,000 | 30,000 | |
TVTX | Travere Therapeutics Inc | 2025-03-31 | Add Add | +1.54% | 17.07 ($20.3) 23.75 | $15.01 | -26.06% | Add 435% | 1,070,000 | 870,000 | |
PTGX | Protagonist Therapeutics Inc | 2025-03-31 | Add Add | +1.29% | 35.09 ($41.9) 59.76 | $51.05 | 21.84% | Add 207.69% | 400,000 | 270,000 | |
NUVL | Nuvalent Inc | 2025-03-31 | Add Add | +1.22% | 67.38 ($78.19) 88.96 | $80.48 | 2.93% | Add 61.4% | 460,000 | 175,000 | |
MLYS | Mineralys Therapeutics Inc | 2025-03-31 | Add Add | +1.17% | 8.76 ($11.5) 16.87 | $14.54 | 26.43% | Add 214.29% | 1,100,000 | 750,000 | |
SYRE | Spyre Therapeutics Inc | 2025-03-31 | Reduce Reduce | -1.14% | 16.14 ($20.81) 24.42 | $15.76 | -24.27% | Reduce -41.57% | 481,678 | -342,650 | |
APGE | Apogee Therapeutics Inc | 2025-03-31 | Add Add | +0.81% | 30.37 ($38.66) 49.57 | $47.46 | 22.76% | Add 23.56% | 1,151,199 | 219,471 | |
ARWR | Arrowhead Pharmaceuticals Inc | 2025-03-31 | Sold Out Sold Out | -0.81% | 12.74 ($18.18) 21.53 | $16.79 | -7.65% | Sold Out | 0 | -300,000 |
Affinity Asset Advisors, LLC Total Holding History ($B)
Affinity Asset Advisors, LLC's Asset Allocation
Affinity Asset Advisors, LLC Past Portfolios
| Portfolio Date | Number of Stocks | New Stocks | Total Value ($Mil) | Q/Q Turnover |
|---|---|---|---|---|
Top Ranked Articles
- 1
Affinity Asset Advisors, LLC's Hypothetical Growth since 2025-03-31
Affinity Asset Advisors, LLC's Yearly Returns
| Year | Portfolio % | % | Excess Gain % |
|---|
Affinity Asset Advisors, LLC's Holdings Heat Map
Size field:
Affinity Asset Advisors, LLC's Holdings Bubble Chart
Affinity Asset Advisors, LLC News
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers